Histone deacetylase inhibitors: emerging mechanisms of resistance

The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma by the U. S. Food...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Robey, Robert W., Chakraborty, Arup R., Basseville, Agnes, Luchenko, Victoria, Bahr, Julian, Zhan, Zhirong, Bates, Susan E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3230675/
https://ncbi.nlm.nih.gov/pubmed/21899343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/mp200329f
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky